NurExone logo2.png
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
January 05, 2024 08:30 ET | NurExone Biologic Inc
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
The PNN as new target for NurExone’s ExoTherapy platform.
NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration
November 29, 2023 08:30 ET | NurExone Biologic Inc
NurExone Biologic expands its portfolio of products to address spinal cord injuries & neuron regeneration in CNS indications
NurExone logo2.png
NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 24, 2023 08:30 ET | NurExone Biologic Inc
NurExone released a corporate update and reported financial results for the quarter ended September 30, 2023.
NurExone.png
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment
October 30, 2023 09:20 ET | NurExone Biologic Inc
NurExone Biologic Receive FDA Orphan-Drug Designation to its ExoPTEN Therapy for Acute Spinal Cord Injury Treatment
NurExone.png
NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy
October 11, 2023 08:30 ET | NurExone Biologic Inc
NurExone has been awarded a grant by the Israel Innovation Authority (“IIA”) as part of the Israel-Canada bilateral Eureka program
NurExone.png
NurExone Biologic to Present Exosome-Based Therapy for Spinal Cord Injury in Regenerative Medicine Session at Upcoming Extracellular Vesicles Forum
October 05, 2023 08:30 ET | NurExone Biologic Inc
NurExone Biologic will present at the EVs Forum in Cambridge presents advances in exosome therapy for spinal cord injuries, highlighting ExoPTEN potential
Zion Market Research.jpg
Global Acellular Therapy Market Size Was Valued at $8.451 Billion in 2022 and Is Projected to Surpass Around $32.61 Billion Mark by 2030, Growing at a CAGR of 16.21%
March 16, 2023 07:02 ET | Zion Market Research
Washington, DC, March 16, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Acellular Therapy Market By Disease (Parkinson’s, Alzeihmer’s, Chronic Wounds,...
Roots-Analysis-Logo.png
The exosome therapeutics market is projected to grow at an annualized rate of 41%, claims Roots Analysis
December 13, 2022 09:00 ET | Roots Analysis
London, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Exosome Therapeutics Market, 2022-2040” report to its list of offerings. With the advancements in...